How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

746 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

the General Practice Research Database (GPRD). The results of the meta-analysis and GPRD analyses informed the economic model supplemented by data from the Health Survey for England and other UK-specific data sourced from the literature.A systematic literature review was conducted of the clinical effectiveness and cost-effectiveness of orlistat, sibutramine and rimonabant within their licensed indications for the treatment of obese patients. Electronic bibliographic databases including MEDLINE, MEDLINE (...) In-Process & Other Non-Indexed Citations, EMBASE, The Cochrane Library databases and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched in January 2009, and the reference lists of relevant articles were checked. Studies were included if they compared orlistat, sibutramine or rimonabant with lifestyle and/or exercise advice (standard care), placebo or metformin.Overall, 94 studies involving 24,808 individuals were included in the clinical meta-analysis. Eighty-three trials

2017 Health technology assessment (Winchester, England)

127. SNAP: a population health guide to behavioural risk factors in general practice

appropriate. For a small number of obese patients (BMI >30 or BMI >27 with other diseases) who do not respond, medical or surgical interventions may need to be considered. Drugs that may be added to education and behavioural interventions include orlistat and sibutramine for long term therapy, and phentermine and diethylpropion for short term use only. Small amounts of weight loss or lack of any increase can be viewed as successes with health gains likely. Any changes made must be able to be maintained

2014 The Royal Australian College of General Practitioners

129. Systematic review with meta-analysis: Orlistat reduces weight but its cost?effectiveness remains unclear

, sibutramine and … Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. Copyright information: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to Read the full text or download the PDF: Subscribe Log in Log

2013 Evidence-Based Nursing

130. Obesity

- release daily dizziness, mild increase in blood pressure and heart rate excreted by kidneys; pregnancy category B; requires blood- pressure monitoring Sibutramine Meridia (Abbott) Approved for weight loss No Inhibition of norepinephrine and serotonin reuptake 5, 10, or 15 mg/day 5% Mild increase in blood pressure and heart rate (rarely more severe), palpitations Pregnancy category C; requires blood- pressure monitoring Orlistat Xenical (Roche); Alli (GlaxoSmithKline) Approved for weight loss No Lipase (...) Organisation, 2011 • Approved for short-term use only; limited data suggest these stimulants may be effective for > 10 years. SibutramineSibutramine is modestly effective in reducing weight, with differing effects on cardiovascular risk and various adverse effect profiles. • Treatment with sibutramine reduced body weight but not blood pressure. • Randomized trials have shown a 5% greater weight reduction in comparison with placebo (but only short-term trials have been carried out; administration

2011 World Gastroenterology Organisation

131. Highlights of the year in Evidence-Based Medicine

as likely to have an x-ray, ultrasound or imaging after seeing a self-employed urologist as opposed to a Staying on the diagnostic theme, we learnt we should not be pooling diagnostic likelihood ratios in . , and Docs suggested women were hitting the pause button on , which sounded very much like the HRT story. On the drug front, we managed to give out 300,000 prescriptions for sibutramine in the . Put me in charge of the drug budget, I’ll show you some cuts. Yet, nearly 1 in 10 prescribed meds were

2011 TrustTheEvidence

132. Can social media data lead to earlier detection of drug‐related adverse events? (PubMed)

Can social media data lead to earlier detection of drug‐related adverse events? To compare the patient characteristics and the inter-temporal reporting patterns of adverse events (AEs) for atorvastatin (Lipitor® ) and sibutramine (Meridia® ) in social media ( versus the FDA Adverse Event Reporting System (FAERS).We identified clinically important AEs associated with atorvastatin (muscle pain) and sibutramine (cardiovascular AEs), compared their patterns in social media (...) postings versus FAERS and used Granger causality tests to assess whether social media postings were useful in forecasting FAERS reports.We analyzed 998 and 270 social media postings between 2001 and 2014, 69 003 and 7383 FAERS reports between 1997 and 2014 for atorvastatin and sibutramine, respectively. Social media reporters were younger (atorvastatin: 53.9 vs. 64.0 years, p < 0.001; sibutramine: 36.8 vs. 43.8 years, p < 0.001). Social media reviews contained fewer serious AEs (atorvastatin, pain: 2.5

Full Text available with Trip Pro

2016 Pharmacoepidemiology and drug safety

133. Analysis of trace amounts of adulterants found in powders/supplements utilizing Raman spectroscopy coupled to direct analyte-probed nanoextraction-nanospray ionization-mass spectrometry (PubMed)

analysis via nanospray of the particulate of interest eliminates time consuming chromatographic techniques prior to mass spectrometry analysis. This coupled technique combines rapid Raman spectroscopy techniques with direct mass spectrometry to confirm the presence of an adulterant. This technique was applied to an FDA supplied test sample, in which sibutramine, phenolphthalein, and melamine were confirmed to be present.

Full Text available with Trip Pro

2016 Analytical methods : advancing methods and applications

134. Effects of Inulin and Arabinoxylan on Satiety, Energy/Food Intake and Changes in the Human Gut Microbiota

/d dietary fibre consumption as well as those with food allergies Gastrointestinal procedure or surgery in the past three months. Gastrointestinal disorders: celiac disease, Intestinal Bowel Disease (IBD), irritable bowel syndrome (IBS), chronic constipation, diverticulitis or a history of chronic constipation, diarrhoea, or other chronic gastrointestinal complaints Disorders of swallowing, severe dysphagia to food or pills. Appetite modulator drugs: orlistat, sibutramine, rimonabant. Mood

2016 Clinical Trials

135. Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis

within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee joint (see section 6.3) End stage disease in target knee joint (Kellgren-Lawrence grade 4) Immuno-inflammatory disease Chronic wide-spread pain Pregnancy or insufficient anti-conception therapy for female fertile patients Breast-feeding Estimated

2016 Clinical Trials

136. Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

absolute or relative contraindication for the conduct of an MRI investigation, such as cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system, metallic splinters in the eye, ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators,cochlear implants, insulin pumps and nerve stimulators, prosthetic heart valves etc. History of bariatric surgery Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed

2016 Clinical Trials

137. The Effect of Hypocaloric Diet Associated With tDCS on Weight Loss and Metabolic Profile

or blood transfusion in the past 8 weeks. Treatment with any oral antidiabetic drugs and / or herbal preparations or medications that do not require a prescription and can affect glycemic control within 12 weeks prior to screening. Chronic treatment with oral or parenteral corticosteroids (> 7 consecutive days of treatment) within 4 weeks prior to screening. Treatment with weight loss agents (e.g., orlistat, sibutramine, topiramate, bupropion) in the last 12 weeks prior to screening. Treatment

2016 Clinical Trials

138. Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans

of treatment, i.e. 7−10 days), tricyclic antidepressants, atypical antipsychotic and mood stabilizers (e.g. imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium); Current participation (or within the last 3 months) in an organized weight reduction program Currently or previous using within 3 months before screening of pramlintide, sibutramine, orlistat, topiramate, or metformin (either

2016 Clinical Trials

139. Does Treating Anxiety Symptoms With ACT Improve Vascular Inflammation and Function?

, Aloprim®). Taking steroids or biologics: corticosteroids (prednisone); methotrexate, infliximib (Remicade®), etaneracept (Enbrel®); anakinra (Kineret®). Vulnerable populations (prisoners, etc.) will not be eligible to participate in this study. Current alcohol abuse. On weight loss drugs (i.e. orilistat (Xenical®), sibutramine (Meridia®), phenylpropanol-amine (Acutrim®)), or similar over-the-counter medications within 3 months of screening. Any condition that, in the view of the PI or Co-I, places

2016 Clinical Trials

140. Effectiveness of Changing Dietary Fat on Weight Loss

of 20-60 years of age. Body Mass Index (BMI) 27.0 -35.0 kg/m2. Not currently taking a prescription medication for weight loss (e.g. orlistat (Xenical®), sibutramine (Meridia®) or phentermine etc.) If subject is willing to discontinue prescription medication(s) immediately and willing to refrain from taking medication(s) for duration of study, he/she may be enrolled after a four-week washout period. Not currently taking any over-the-counter weight loss supplement(s) or appetite suppressants

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>